Thomas S Kupper

USPTO Granted Patents = 11 (Patent Applications = 6)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 11(Granted Patents)

Location History:

Weston, MA (US) (2005 - 2016)
Belmont, MA (US) (2015 - 2020)

Company Filing History:

8 out of 1,373

The Brigham and Women's Hospital, Inc.

patents

5 out of 1,210

Dana-farber-cancer Institute Inc.

The Bingham and Women's Hospital

patents

5. 1 out of 10

The Cbr Institute for Biomedical Research, Inc.

patents

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319970 - Methods for identifying progression of a primary melanoma (2025-06-03),

2. 10584172 - Humanized monoclonal antibodies and methods of use (2020-03-10),

3. 9629910 - Use of Th9 cells and IL-9 for the treatment of melanoma (2017-04-25),

4. 9587028 - Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use (2017-03-07),

5. 9441045 - Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use (2016-09-13),

6. 9416371 - T-cell vaccination with viral vectors via mechanical epidermal disruption (2016-08-16),

7. 9416169 - Humanized monoclonal antibodies and methods of use (2016-08-16),

8. 8962806 - Humanized monoclonal antibodies and methods of use (2015-02-24),

9. 8691502 - T-cell vaccination with viral vectors via mechanical epidermal disruption (2014-04-08),

10. 7402432 - Process for producing T lymphocytes (2008-07-22),

11. 6929792 - Modified dendritic cells and use therefor (2005-08-16),

Title: The Innovations of Thomas S. Kupper

Introduction

Thomas S. Kupper is a prominent inventor based in Weston, MA, known for his significant contributions to the field of cancer research. With a total of 11 patents to his name, Kupper has made remarkable strides in understanding and treating melanoma, a serious form of skin cancer. His work has not only advanced scientific knowledge but has also paved the way for new therapeutic approaches.

Latest Patents

Among his latest patents, Kupper has developed methods for identifying the progression of primary melanoma. This innovative approach utilizes T cell frequency (TCFR) as a predictor of disease progression and survival in patients. By employing high throughput DNA sequencing of the TCRB gene, Kupper's methods aim to enhance patient selection and treatment strategies. Additionally, he has created humanized monoclonal antibodies that bind to the chemokine receptor CCR4. This antibody, derived from Mab 1567, inhibits ligand-mediated activities and is utilized in treating cancer symptoms. Furthermore, it can be combined with vaccines to suppress the activity of regulatory T cells, showcasing Kupper's commitment to advancing cancer therapies.

Career Highlights

Kupper has had a distinguished career, working with esteemed institutions such as Brigham and Women's Hospital and Dana-Farber Cancer Institute. His research has been instrumental in developing innovative solutions for cancer treatment, particularly in the realm of melanoma.

Collaborations

Throughout his career, Kupper has collaborated with notable colleagues, including Wayne A. Marasco and Jianhua Sui. These partnerships have contributed to the success of his research and the development of his patents.

Conclusion

Thomas S. Kupper's contributions to cancer research and treatment through his patents and collaborations highlight his role as a leading inventor in the field. His innovative methods and dedication to improving patient outcomes continue to make a significant impact in the medical community.

This text is generated by artificial intelligence and may not be accurate.